Shape 21 Experience

    The Enhanced Liver Fibrosis (ELF™) Test1,2

    A Simple Blood Test to Assess Risk of NAFLD Progression & Liver-Related Events​

    NAFLD impacts 25% globally3

    Because of the increasing global burden, lack of appropriate non-invasive testing options is a major concern

    Assessment of liver fibrosis has traditionally relied on costly and invasive liver biopsy that requires a specialist, may not be representative of the amount of fibrosis, and carries a risk of life-threatening complications.​

    Liber Fibrosis hotspot image
    1. A true silent killer, liver disease often does not show signs or symptoms.

    2. Many patients go undetected and remain in primary care.​

    3. Patient is then referred to a specialist by their PCP​.

    4. Complications of advanced fibrosis start to develop.

    5. Earlier assessment and monitoring were needed. The evolution of non-invasive liver fibrosis tests has created the opportunity to improve the detection of cases in patients while reducing unnecessary referrals to secondary care and reducing healthcare costs.​

    6. Patient finds out there is irreversible damage and/or is presenting with end stage liver disease​.

    Click to watch video

    In this video, Dr. Zobair M. Younossi, Professor and Chairman of the Department of Medicine at Inova Fairfax Hospital in Falls Church, Virginia, discusses the epidemiology of nonalcoholic fatty liver disease (NAFLD), addressing why there is a global need for more awareness and why the current approach to clinical care needs to change.​

    The Enhanced Liver Fibrosis (ELF) Blood Test Literature Compendium

    The performance of the ELF Test for liver fibrosis has been well-established in scientific literature, and ease of testing and interpretation support routine clinical use as an alternative to invasive biopsy. This compendium highlights a small subset of the extensive number of ELF publications and provides an introduction to the ELF Test.​